This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Cooper Companies Announces Third Quarter 2012 Results

PLEASANTON, Calif., Sept. 6, 2012 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced financial results for the fiscal third quarter ended July 31, 2012.

  • Revenue increased 8% year-over-year to $378.2 million. CooperVision (CVI) revenue up 5% to $314.2 million and CooperSurgical (CSI) revenue up 20% to $64.0 million.
  • GAAP earnings per share (EPS) $1.36, up 46 cents or 51% from last year's third quarter.
  • Non-GAAP EPS $1.45, up 30 cents from last year's third quarter. See "Reconciliation of Non-GAAP EPS to GAAP EPS" below.
  • Free cash flow $62.9 million.

Commenting on the results, Robert S. Weiss, Cooper's president and chief executive officer said, "I'm very proud of the progress we made this quarter. We continued to execute on our long-range objectives with CooperVision gaining market share and CooperSurgical posting another strong quarter. We also closed on the acquisition of Origio, the leading global in-vitro fertilization (IVF) medical device company. Our business continues to perform well and we remain optimistic about continuing to deliver strong results."

Third Quarter GAAP Operating Highlights

  • Revenue $378.2 million, 8% above third quarter 2011, 9% excluding currency and acquisitions.
  • Gross margin 63% compared with 58% in last year's third quarter. The improvement was the result of improved margins at both CooperVision and CooperSurgical, and the $14.2 million Avaira ® recall reserve for inventory and return provisions in last year's third quarter.
  • Operating margin 20% compared with 15% in last year's third quarter. The improvement was primarily the result of gross margin improvements.
  • Depreciation $21.9 million, up 10% from last year's third quarter. Amortization $5.9 million, up 7% from last year's third quarter primarily related to additional amortization from the acquisition of Origio.
  • Total debt increased $160.8 million from April 30, 2012, to $480.1 million due mainly to the Origio acquisition. Interest expense was $2.3 million compared with $3.2 million in last year's third quarter. Excluding a $0.4 million gain associated with the Origio acquisition, interest expense would have been $2.7 million.
  • Cash provided by operations $78.1 million, capital expenditures $24.1 million, insurance recovery $1.9 million and excluding Origio related costs of $7.0 million, free cash flow $62.9 million. 

Third Quarter CooperVision GAAP Operating Highlights

  • Revenue $314.2 million, up 5% from last year's third quarter, 10% in constant currency.  
  • Revenue by category:  
        Constant Currency
  (In millions) % of CVI Revenue %chg %chg
  3Q12 3Q12 y/y y/y
Toric  $ 94.7 30% 7% 12%
Multifocal  24.8 8% 26% 33%
Single-use sphere  71.7 23% 11% 13%
Non single-use sphere, other  123.0 39% -2% 3%
Total  $ 314.2 100% 5% 10%
  • Revenue by geography:
        Constant Currency
   (In millions)  % of CVI Revenue %chg %chg
   3Q12  3Q12 y/y y/y
Americas  $ 131.3 42% 10% 11%
EMEA  106.5 34% -5% 6%
Asia Pacific  76.4 24% 16% 16%
Total  $ 314.2 100% 5% 10%
  • Selected revenue by material:
        Constant Currency
   (In millions)  % of CVI Revenue %chg %chg
   3Q12  3Q12 y/y y/y
         
Silicone hydrogel  $ 117.9 38% 28% 35%
Proclear®  $ 79.0 25% -2% 3%
  • Gross margin 63% compared with 56% in the third quarter of 2011. The improvement was the result of the $14.2 million Avaira ® recall reserve for inventory and return provisions in last year's third quarter as well as increased manufacturing efficiencies and favorable product mix, primarily from a shift to higher margin silicone hydrogel products.

Third Quarter CooperSurgical GAAP Operating Highlights

  • Revenue $64.0 million, up 20% from last year's third quarter. Revenue includes $5.6 million from the Origio acquisition and was up 6% excluding acquisitions.  
  • Revenue by category:
       
  (In millions) % of CSI Revenue %chg
  3Q12 3Q12 y/y
Office, other  $ 30.8 48% 7%
Surgical procedures  23.7 37% 16%
Fertility  9.5 15% 149%
Total  $ 64.0 100% 20%
  • Gross margin 67%, up from 65% in last year's third quarter. The improvement in gross margin was largely a result of manufacturing efficiency improvements and favorable product mix resulting primarily from a shift to higher margin products used in surgical procedures. This was slightly offset by lower gross margins from Origio. 

Other Items

  • On May 31, 2012, entered into an amendment to our senior unsecured revolving line of credit. Facility increased to $1.0 billion from $750.0 million, and the $234.4 million term loan was fully repaid using the new revolving facility. The facility offers additional availability, lower interest rates and extends the maturity date to May 31, 2017, from January 12, 2016. 
  • On July 11, 2012, completed the voluntary tender offer for Origio, a leading global in-vitro fertilization (IVF) medical device company based in Denmark. 
  • During the quarter, repurchased approximately 321,000 shares for $25.0 million. Fiscal year-to-date repurchases now total approximately 984,000 shares for $71.1 million.

2012 Guidance

The Company revises its full-year fiscal 2012 revenue and EPS guidance. Guidance is summarized as follows:

  2012 Guidance 2012 Guidance 4Q12 Guidance
  Old New New
Revenues (In millions)      
Total $1,400--$1,440 $1,439--$1,449 $390--$400
CooperVision $1,175--$1,205 $1,186--$1,191 $315--$320
CooperSurgical $225--$235 $253--$258 $75--$80
EPS      
GAAP $4.88--$5.13 $5.10--$5.15 $1.50--$1.55
Non-GAAP $4.90--$5.15 $5.19--$5.24 $1.50--$1.55
Free Cash Flow (In millions) $200--$230 $210--$230 $63--$83

Guidance assumes constant currency at the date of issuance and no pending acquisitions. See "Reconciliation of Non-GAAP EPS to GAAP EPS" below.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs